These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 5822586)

  • 1. Partial purification and properties of a plasminogen activator from human erythrocytes.
    Semar M; Skoza L; Johnson AJ
    J Clin Invest; 1969 Oct; 48(10):1777-85. PubMed ID: 5822586
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasminogen-activator in human early milk: its partial purification and characterization.
    Okamoto U; Horie N; Nagamatsu Y; Yamamoto JI
    Thromb Haemost; 1981 Apr; 45(2):121-6. PubMed ID: 7196095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro studies on the fibrinolytic, thrombolytic and fibrinogenolytic properties of a tissue plasminogen activator from guinea pig keratocytes.
    Electricwala A; Ling RJ; Sutton PM; Griffiths B; Riley PA; Atkinson T
    Thromb Haemost; 1985 Apr; 53(2):200-3. PubMed ID: 4040659
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Blood fibrinolytic system in rana tigrina.
    Srivastava VM; Dube B; Dube RK; Agarwal GP; Ahmad N
    Thromb Haemost; 1981 Jun; 45(3):252-4. PubMed ID: 7281104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the relative fibrinogenolytic, fibrinolytic and thrombolytic properties of tissue plasminogen activator and urokinase in vitro.
    Matsuo O; Rijken DC; Collen D
    Thromb Haemost; 1981 Jun; 45(3):225-9. PubMed ID: 7025339
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of erythrocytes on fibrinolysis].
    Haematologia (Budap); 1975; 9(1-2):85-96. PubMed ID: 820611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Isolation of tissue plasminogen activator from skin lesions with allergic vasculitis.
    Toki N; Tsushima H; Yamasaki M; Yamasaki R; Yamura T
    J Invest Dermatol; 1982 Jan; 78(1):18-23. PubMed ID: 7198668
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complementary modes of action of tissue-type plasminogen activator and pro-urokinase by which their synergistic effect on clot lysis may be explained.
    Pannell R; Black J; Gurewich V
    J Clin Invest; 1988 Mar; 81(3):853-9. PubMed ID: 2963831
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Purification and characterization of a novel fibrinolytic enzyme from Streptomyces spp.
    Wang J; Wang M; Wang Y
    Chin J Biotechnol; 1999; 15(2):83-9. PubMed ID: 10719627
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of plasminogen in vitro or during thrombolytic therapy limits fibrinolytic potential.
    Onundarson PT; Francis CW; Marder VJ
    J Lab Clin Med; 1992 Jul; 120(1):120-8. PubMed ID: 1613318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Method of estimating the inhibitory effect of plasma or serum upon urokinase-activated fibrinolysis.
    Mann RD
    J Clin Pathol; 1966 May; 19(3):233-7. PubMed ID: 5937607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cleavage of surfactant-incorporating fibrin by different fibrinolytic agents. Kinetics of lysis and rescue of surface activity.
    Günther A; Markart P; Kalinowski M; Ruppert C; Grimminger F; Seeger W
    Am J Respir Cell Mol Biol; 1999 Dec; 21(6):738-45. PubMed ID: 10572071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the activation mechanism of fibrinolytic enzyme system in plasma by human pancreatic elastase.
    Toki N; Takasugi S; Ishizu K; Sato H; Sumi H
    Thromb Haemost; 1982 Feb; 47(1):8-13. PubMed ID: 6176043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of retraction on the lysis of human clots with fibrin specific and non-fibrin specific plasminogen activators.
    Sabovic M; Lijnen HR; Keber D; Collen D
    Thromb Haemost; 1989 Dec; 62(4):1083-7. PubMed ID: 2515603
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator content of human tumor and adjacent normal tissue measured with fibrin and non-fibrin assays.
    Camiolo SM; Greco WR
    Cancer Res; 1986 Apr; 46(4 Pt 1):1788-94. PubMed ID: 3081257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Purification of rabbit kidney cytokinase and a comparison of its properties with human urokinase.
    Ali SY; Evans L
    Biochem J; 1968 Mar; 107(2):293-303. PubMed ID: 5641883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A method for separation of plasminogen from bovine plasma fraction. I. With reference to some properties of the plasminogen].
    Okamoto U; Matumoto M
    Nihon Seirigaku Zasshi; 1971; 33(7):394-402. PubMed ID: 4255047
    [No Abstract]   [Full Text] [Related]  

  • 18. Resistance of porcine blood clots to lysis relates to poor activation of porcine plasminogen by tissue plasminogen activator.
    Flight SM; Masci PP; Lavin MF; Gaffney PJ
    Blood Coagul Fibrinolysis; 2006 Jul; 17(5):417-20. PubMed ID: 16788320
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The plasminogen activator of vampire bat saliva.
    Cartwright T
    Blood; 1974 Mar; 43(3):317-26. PubMed ID: 4204546
    [No Abstract]   [Full Text] [Related]  

  • 20. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR; De Wreede K; Demarsin E; Collen D
    Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.